The claim: Genflow Biosciences says its SIRT6 gene therapy lowered a DNA methylation measure of biological age in older beagles.
The evidence: The 24-dog SLAB study was randomized and blinded, with saline controls and three treatment groups. That design is more informative than an uncontrolled observation. But Genflow has not yet released the numerical results, effect sizes, full statistics or underlying dataset. For now, the result is an interesting company-reported signal, not proof that aging was reversed.
Can a gene therapy make an old dog biologically younger? Genflow Biosciences says its completed trial produced just such a signal. The more immediate question is whether outsiders can evaluate it.
In a September 8 announcement, the company said its Sarcopenia and Longevity in Aged Beagles study, known as SLAB, met its primary endpoint. Treated animals reportedly scored as biologically younger than saline-treated controls on a DNA methylation clock. Genflow also reported improvements in functional and observable secondary measures.
What the trial tested
The randomized, blinded study enrolled 24 beagles older than 10. The dogs were divided into four groups: two received different doses of a naked-DNA treatment, one received a single dose delivered with an adeno-associated virus called AAV8, and one received saline.
Naked DNA delivers genetic instructions without packaging them inside a virus. AAV8 uses a modified virus as a delivery vehicle. Both approaches aimed to supply a version of SIRT6 associated with exceptional human longevity.
Randomization matters because it reduces the chance that healthier dogs happened to enter the treatment groups. Blinding matters because people measuring performance can be influenced, even unintentionally, by knowing which animals were treated. A saline control gives the researchers a comparison for changes that might occur with time, handling or chance.
Why SIRT6 attracts longevity researchers
SIRT6 is a protein-producing gene involved in DNA repair, genome stability, metabolism and the control of inflammatory signals. Those processes are closely connected to how cells respond to stress and accumulate damage with age.
Animal experiments and studies of unusually long-lived people have made SIRT6 a prominent target in geroscience. That biological rationale is useful, but it does not establish that adding a SIRT6 variant will safely improve health or extend life. A plausible mechanism is the beginning of a case, not the conclusion.
What a methylation clock can show
DNA methylation is a chemical tagging system that helps regulate gene activity. Patterns at many sites across the genome change with age. An epigenetic clock uses those patterns to estimate an age-related score.
Genflow says the trial used a GRIM methylation clock. A lower score after treatment could mean the therapy altered molecular patterns associated with aging. It does not mean a dog literally became younger, and it does not by itself show better health, slower disease development or longer life.
Clocks can respond to changes in cell composition, inflammation and other biological processes. Their predictions also depend on how they were trained and validated. To interpret this result, readers need to know the size and consistency of the changes, the clock’s validation in aged beagles, baseline balance between groups, the analysis plan and how missing samples were handled.
The missing data are the main limitation
Genflow says treated dogs showed a clear improvement signal relative to controls and that several secondary measures also improved. The announcement does not provide group-level numbers, effect sizes, confidence intervals, exact P values or the complete dataset. It also does not specify which secondary measures improved or whether they were selected in advance.
With only 24 dogs split across four groups, each group is necessarily small. That makes individual animals influential and raises the importance of transparent statistics. Multiple treatment arms and secondary outcomes can also increase the chance of apparently positive findings unless the analysis accounts for multiple comparisons.
The company plans to present mechanistic analyses and detailed results at the Animal Longevity Summit in Toronto on October 2, 2026. A full report should make it possible to examine safety, all prespecified outcomes, the magnitude and durability of the methylation change, and whether the functional results line up with the clock.
Why dogs are interesting, but not human evidence
Dogs share human environments, develop many age-related conditions naturally and have greater genetic and physiological complexity than laboratory mice. Their shorter lives also make long-term outcomes more practical to study. Those features can make canine results especially useful for translational research.
Still, this was a small study in one dog breed. A result in beagles cannot establish safety or effectiveness in people. Even strong canine evidence would need to be followed by careful human trials, particularly because gene therapy can carry delivery, immune and long-term safety risks.
The Lifespan Brief verdict
A randomized, blinded, controlled trial in naturally aged dogs is a meaningful step beyond a laboratory observation. Genflow’s report that the primary endpoint was met deserves attention.
But the public evidence currently stops at the company’s description of the result. Without the numbers and methods needed to judge the finding, claims of age reversal go too far. The October presentation may sharpen the picture. Until then, the responsible conclusion is that SIRT6 gene therapy produced a promising biomarker signal in old dogs according to its developer, not that it made them truly younger.
Sources
- Genflow Meets Primary Endpoint in SLAB Clinical Trial, Genflow Biosciences, September 8, 2026.
- Genflow clinical programs and SLAB study overview.
This article is for general information and is not medical or investment advice.